
Atypical Anti-Glomerular Basement Membrane Disease With Diffuse Crescentic Membranoproliferative Glomerulonephritis: Case Report and Review of Literature
Author(s) -
Mostafa Elshirbeny,
Mohamad Alkadi,
Imaad Mujeeb,
Omar Fituri
Publication year - 2020
Publication title -
qatar medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.171
H-Index - 9
eISSN - 2227-0426
pISSN - 0253-8253
DOI - 10.5339/qmj.2020.16
Subject(s) - medicine , rapidly progressive glomerulonephritis , membranoproliferative glomerulonephritis , pathology , nephrotic syndrome , proteinuria , renal biopsy , glomerulonephritis , biopsy , gastroenterology , kidney
Anti-glomerular basement membrane (anti-GBM) disease occurs in fewer than two cases per million population. Patients usually present with features of rapidly progressive glomerulonephritis (RPGN) with or without pulmonary involvement. Anti-GBM disease is classically diagnosed by both demonstrating GBM linear immunofluorescence staining on kidney biopsy and detecting anti-GBM antibodies in serum. More than 90% of patients with anti-GBM disease either become dialysis-dependent or die if left untreated. Here, we report a 37-year-old man who presented with bilateral lower limb edema, hypertension, acute kidney injury (creatinine of 212 μmol/L), microscopic hematuria, and nephrotic range proteinuria (15 g/day). His kidney biopsy showed diffuse crescentic membranoproliferative glomerulonephritis and bright linear staining of GBM by immunoglobulin G consistent with anti-GBM disease; however, serum anti-GBM antibodies were negative. The patient was diagnosed with atypical anti-GBM disease and treated aggressively with intravenous pulse steroids, plasmapheresis, oral cyclophosphamide, and oral prednisolone with significant improvement in kidney function and proteinuria. Atypical anti-GBM disease should be considered in patients presenting with RPGN, even in the absence of serum anti-GBM antibodies. Early diagnosis and aggressive treatment in such cases are warranted to prevent irreversible kidney damage as the course of the disease might not be as benign as previously thought.